Intensification of metallo-enzyme production to unlock sustainable biocatalytic hydrogenation

强化金属酶生产以实现可持续的生物催化氢化

• 批准号: 10065700
• 金额: $ 9.08万
• 依托单位: HYDREGEN LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10065700
• 关键词: Intensification; metallo; enzyme; production; unlock

**HydRegen** is a 2021 spin-out from the University of Oxford's Department of Chemistry.**Our vision:** The HydRegen technologies offer the potential for cleaner, safer, faster and cheaper chemical manufacture.Deep understanding of biology and chemistry allow the HydRegen team to select the best components from biology and use them to develop robust biotechnologies that solve real problems in the chemicals sectors.We expect our technologies to play a part in the UK chemicals sector meeting ambitious Net Zero emissions targets (by 2050) and increasing adoption of enabling technologies such as Industrial Biocatalysis and continuous flow process.Currently we are addressing challenges in the manufacture of pharmaceuticals and speciality chemicals (e.g. flavours and fragrances) and exploring the potential of our technologies for larger-scale, lower-value chemical production.**Dr Morra's Group (University of Nottingham)** have expertise in novel hydrogenase enzymes that are able to cycle H2 and H+. Theses enzymes are of interest to HydRegen due to their unusual balance in 'ease of production' and 'ease of handling'. Dr Morra's team have know-how and facilities in enzyme production spanning early-stage academic research through to evaluation of scalable enzyme production in bioreactors (up to 100L).**Project focus:** here we tackle challenges in manufacturing readiness of the HydRegen technologies by intensifying and scaling enzyme production, and applying the enzyme generated to a demonstrator process for quinuclidinol production. Quinuclidinol is an important chemical building-block present in a number of active pharmaceuticals.Dr Morra and HydRegen started their collaboration in 2022 via BBSRC-NIBB funding. This project allows both partners to realise the potential of this collaboration.**Project outputs:*** Lower cost-of-production of three enzymes that are critical to HydRegen.* Use of these enzymes for production of chemical building-block quninuclidinol at \>10g scale.* Validation of the cost and sustainability metrics for quinuclidinol manufacture.* New IP (enzyme production, biocatalyst formulation, process chemistry).* 'License-ready' bio-based manufacturing route for quinuclidinol that meets the needs for UK-based production (cost, foot-print, productivity, safety, sustainability).

** hydregen **是牛津大学化学系的2021年拆分。在英国化学品中发挥作用的技术，达到雄心勃勃的零排放目标（到2050年），并越来越多地采用了诸如工业生物催化和持续流动过程之类的能力技术，我们虽然正在解决药物和特种化学物质的挑战（例如，较较大的化学方法），并在较较大的技术中探索我们的较大的技术，我们的技术是较大的，我们的技术，我们的技术，我们的技术，我们的技术较大，我们的技术是，我们的化学方法是我们的​​较大的技术，我们正在解决我们的挑战。生产。**莫拉博士的小组（诺丁汉大学）**具有能够循环H2和H+的新型氢化酶酶的专业知识。 Hydregen在“易于生产”和“易于处理”方面的异常平衡，这是Hydregen感兴趣的。莫拉博士的团队在酶生产方面拥有专有技术和设施，跨越早期学术研究，以评估生物反应器中的可扩展酶生产（最高100L）。奎尼核苷酸是许多活跃的药物中存在的重要化学建筑块。DrMorra和Hydregen于2022年通过BBSRC-NIBB资助开始了他们的合作。这个项目使双方都可以意识到这项合作的潜力。化学）。*基于Quinuclidinol的基于“许可证”的生物制造路线，可满足英国生产需求（成本，脚印，生产力，安全性，可持续性）。